|
|
|
|
The sterile manufacturing industry is undergoing a transformation as regulatory agencies shift towards a comprehensive approach to compliance. We explore the implications of recent updates, such as those to Annex 1, that form a framework for their compliance strategies.
|
|
|
|
|
Drawing on leadership lessons from the U.S. Army and decades in biopharma manufacturing, a CDMO CEO discusses operational excellence, sterile fill-finish challenges, strategic focus, and building resilient organizations that deliver reliable drug supply.
|
|
|
|
|
The rise of high-volume biologics and home-based care requires specialized expertise in sterile filling and device integration. Discover how collaborative manufacturing partnerships bridge the gap between drug-delivery requirements and successful commercial market entry.
|
|
|
|
|
The shift toward patient-centric care requires integrated fill/finish strategies and modular manufacturing. By leveraging early-stage collaborations and flexible delivery systems, developers can navigate complex regulatory landscapes while accelerating the delivery of safe, self-administered injectable therapies.
|
|
|
|
|
|
|
A new sterile fill/finish facility and advanced filling line expand capacity, flexibility, and quality oversight, helping accelerate the path from clinical development to commercial supply.
|
|
|
|
|
|
|
Partner with an experienced CDMO for rigorous quality control, flexible fill/finish capacity, and FDA/EU-approved lines supporting secure biopharmaceutical commercialization.
|
|
|
|
|
|
|
